Laurie Stelzer - Nov 22, 2023 Form 4 Insider Report for Spyre Therapeutics, Inc. (AGLE)

Role
Director
Signature
/s/ Heidy King-Jones, as Attorney-in-Fact
Stock symbol
AGLE
Transactions as of
Nov 22, 2023
Transactions value $
$0
Form type
4
Date filed
11/27/2023, 04:33 PM
Previous filing
Aug 10, 2023
Next filing
May 16, 2024

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction AGLE Stock Option (Right to Buy) Award $0 +50K $0.00 50K Nov 22, 2023 Common Stock 50K $10.39 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 This option represents a right to purchase 50,000 shares of the Issuer's common stock, which will vest and become exercisable in 36 equal monthly installments beginning on November 22, 2023 until such time as the option is 100% vested, subject to the Reporting Person's continuous service with the Issuer at each vesting date.